Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Elbelt, U; Schlaffer, SM; Buchfelder, M; Knappe, UJ; Vila, G; Micko, A; Deutschbein, T; Unger, N; Lammert, A; Topuzoglu-Müller, T; Bojunga, J; Droste, M; Johanssen, S; Kolenda, H; Ritzel, K; Buslei, R; Strasburger, CJ; Petersenn, S; Honegger, J.
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
J Clin Endocrinol Metab. 2020; 105(3):
Doi: 10.1210/clinem/dgz211
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Micko Alexander
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- CONTEXT: Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging. OBJECTIVE: We therefore aimed to report on clinical characteristics leading to initiation of TMZ therapy and to add evidence on TMZ long-term effectiveness. DESIGN AND SUBJECTS: Retrospective survey on TMZ treatment in patients with APTs or PCs. TMZ therapy was initiated in 47 patients (22 females) with APTs (n = 34) or PCs (n = 13). Mean age at diagnosis was 45 ± 15 years. The immunohistochemical subtypes were corticotroph (n = 20), lactotroph (n = 18), and nonfunctioning (n = 9) tumors. TMZ therapy started 8 years after initial diagnosis using a standard regimen (median 6 cycles) for the majority of patients. RESULTS: Long-term radiological response to TMZ after a median follow-up of 32 months with 4 patients still on TMZ therapy was tumor regression for 9 (20%), stable disease for 8 (17%), and tumor progression for 29 patients (63%) (outcome data available for 46 patients). Progression occurred 16 months after initiation of TMZ. Median estimated progression-free survival was 23 months. Disease stabilization and median progression-free survival did not differ between patients with APTs or PCs. Predictors of tumor response were not identified. Overall, TMZ was well tolerated. CONCLUSION: We performed a nationwide survey on TMZ therapy in patients with APTs and PCs. While early response rates to TMZ are promising, long-term outcome is less favorable. Prolonged TMZ administration should be considered. We were not able to confirm previously reported predictors of tumor response to TMZ.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenoma - drug therapy
- Adult - administration & dosage
- Antineoplastic Agents, Alkylating - therapeutic use
- Carcinoma - drug therapy
- Female - administration & dosage
- Germany - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Pituitary Neoplasms - drug therapy
- Retrospective Studies - administration & dosage
- Temozolomide - therapeutic use
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- aggressive pituitary tumor
- pituitary carcinoma
- progression-free survival
- response rate
- temozolomide